The Nifty Healthcare index has 20 stocks: Abbott India, Alkem Laboratories, Apollo Hospitals, Aurobindo Pharma, Biocon, Cipla, Divi's Laboratories, Dr. Reddy's Laboratories, Fortis Healthcare, Glenmark Pharmaceuticals, IPCA Laboratories, Laurus Labs, Lupin, Mankind Pharma, Max Healthcare, P&G Health, Sun Pharma, Syngene International, Torrent Pharmaceuticals, and Zydus Lifesciences. Maintained by NSE India, it is the primary benchmark for India's healthcare and pharmaceutical sector.
What Is the Nifty Healthcare Index?
The Nifty Healthcare index is a free-float market capitalisation-weighted sectoral index maintained by NSE India. It covers companies across pharmaceuticals (generics, branded generics, biologics, APIs), hospitals, and healthcare services. According to NSE India, the index is rebalanced semi-annually in March and September. It is broader than the Nifty Pharma index — adding hospital chains and contract research/manufacturing alongside drug manufacturers.
All 20 Nifty Healthcare Index Stocks — Complete List
| Company | NSE Symbol | Sub-Sector | Earnings Page |
|---|---|---|---|
| Abbott India Ltd. | ABBOTINDIA | Branded pharma | ABBOTINDIA/earnings |
| Alkem Laboratories Ltd. | ALKEM | Branded generics | ALKEM/earnings |
| Apollo Hospitals Enterprise Ltd. | APOLLOHOSP | Hospitals | APOLLOHOSP/earnings |
| Aurobindo Pharma Ltd. | AUROPHARMA | Generic pharma | AUROPHARMA/earnings |
| Biocon Ltd. | BIOCON | Biologics/Biosimilars | BIOCON/earnings |
| Cipla Ltd. | CIPLA | Generic pharma | CIPLA/earnings |
| Divi's Laboratories Ltd. | DIVISLAB | API/CRAMS | DIVISLAB/earnings |
| Dr. Reddy's Laboratories Ltd. | DRREDDY | Generic pharma | DRREDDY/earnings |
| Fortis Healthcare Ltd. | FORTIS | Hospitals | FORTIS/earnings |
| Glenmark Pharmaceuticals Ltd. | GLENMARK | Branded generics | GLENMARK/earnings |
| IPCA Laboratories Ltd. | IPCALAB | Generic pharma/API | IPCALAB/earnings |
| Laurus Labs Ltd. | LAURUSLABS | API/Generic pharma | LAURUSLABS/earnings |
| Lupin Ltd. | LUPIN | Generic pharma | LUPIN/earnings |
| Mankind Pharma Ltd. | MANKIND | Branded generics | MANKIND/earnings |
| Max Healthcare Institute Ltd. | MAXHEALTH | Hospitals | MAXHEALTH/earnings |
| P&G Health Ltd. | PPLPHARMA | OTC/Consumer health | PPLPHARMA/earnings |
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | Generic/Specialty pharma | SUNPHARMA/earnings |
| Syngene International Ltd. | SYNGENE | CRAMS/CRO | SYNGENE/earnings |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | Branded generics | TORNTPHARM/earnings |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | Generic pharma | ZYDUSLIFE/earnings |
Understanding the Nifty Healthcare Sector
Pharma generics dominate by count but hospitals are growing fast. Sun Pharma, Dr. Reddy's, Cipla, Lupin, and Aurobindo are India's five largest generic pharmaceutical companies — all with significant US generic drug revenues. The US FDA pipeline, ANDA approvals, and pricing dynamics in the US market are critical earnings drivers for all five.
Branded generics are a distinct India story. Mankind Pharma, Alkem, Torrent, and Abbott India are primarily India-domestic branded generics players. These companies charge premium prices over commodity generics by investing in brand equity with doctors. They tend to have higher margins and more stable domestic revenue than US-generic-focused players.
Hospitals are the fastest-growing sub-segment. Apollo Hospitals, Fortis Healthcare, and Max Healthcare are major hospital chains benefiting from India's healthcare infrastructure gap — rising middle-class demand, health insurance penetration, and medical tourism. Hospital companies have long capex cycles but high revenue visibility once beds are commissioned.
API and CRAMS are the supply chain backbone. Divi's Laboratories and Syngene serve global pharma companies as Active Pharmaceutical Ingredient (API) manufacturers and contract research/manufacturing (CRAMS) partners. They benefit from China+1 diversification trends as global pharma companies reduce dependence on Chinese API suppliers.
Biologics and biosimilars are next-generation growth. Biocon — through its Biocon Biologics subsidiary — is building a global biosimilars portfolio targeting insulin, immunosuppressants, and oncology. Biosimilars offer higher margins than small-molecule generics but require more complex manufacturing and regulatory approvals.
Key Drivers of Nifty Healthcare Performance
What moves this sector:
- US FDA approvals and import alerts — a single FDA warning letter can wipe 10-20% off a pharma company's stock
- US generic drug pricing — a structurally deflationary market with periodic sharp price declines
- India domestic formulations growth — driven by chronic disease prevalence, doctor reach, and brand building
- Hospital occupancy and ARPOBs (Average Revenue Per Occupied Bed) — key metric for hospital chains
- API price trends — Chinese API dumping pressure vs India cost competitiveness
- Currency (INR/USD) — US revenue companies benefit from INR weakness
Defensive characteristics: Healthcare is less cyclical than metals or IT. Domestic pharma demand is relatively inelastic — people don't stop buying medicines in a downturn. Hospital revenues are more stable than industrial sectors. This makes Nifty Healthcare a partial defensive play within the broader market.
How to Research Nifty Healthcare Stocks on StockMirror
Healthcare earnings are complicated — FDA filings, pipeline launches, ANDA approvals, API cost pressures, and hospital bed additions all matter. What's harder to track from financial tables is whether management is being transparent about FDA risks, how US pricing is really trending, and whether hospital expansion margins are holding.
The StockMirror AI Analyst reads actual earnings call transcripts to surface what management said about US generic pricing, FDA status, and margin guidance. The /screener shows 16 AI signals — including Earnings Quality, Margin Direction, and Management Confidence — for all 20 Nifty Healthcare stocks at once.
Key Takeaways
- Nifty Healthcare has 20 stocks spanning generics, branded pharma, biologics, hospitals, and CRAMS
- Sun Pharma, Dr. Reddy's, Cipla, and Apollo Hospitals are the largest constituents by market cap
- US generic drug revenues are a key swing factor for the export-focused pharma companies
- Hospital chains (Apollo, Fortis, Max Healthcare) are in a long-term growth cycle driven by India's healthcare infrastructure gap
- The index is broader and more diversified than the older Nifty Pharma index
- Semi-annually rebalanced by NSE in March and September
FAQ
What stocks are in the Nifty Healthcare index? 20 stocks: Abbott India, Alkem, Apollo Hospitals, Aurobindo, Biocon, Cipla, Divi's Labs, Dr. Reddy's, Fortis Healthcare, Glenmark, IPCA Labs, Laurus Labs, Lupin, Mankind Pharma, Max Healthcare, P&G Health, Sun Pharma, Syngene, Torrent Pharma, and Zydus Lifesciences.
How many stocks are in Nifty Healthcare? 20 stocks — 14 pharma/biotech companies and hospitals/healthcare services including Apollo, Fortis, and Max Healthcare.
What is Nifty Healthcare? NSE India's primary sectoral index for healthcare — free-float market cap weighted, rebalanced semi-annually. Covers pharma manufacturers, hospital chains, API makers, and CRAMS companies.
What is the difference between Nifty Healthcare and Nifty Pharma? Nifty Pharma has 10 pure pharma stocks. Nifty Healthcare is broader with 20 stocks including hospitals (Apollo, Fortis, Max), biologics (Biocon), and CRAMs (Syngene).
How can I invest in Nifty Healthcare stocks? Buy individual stocks via any NSE broker, or through Nifty Healthcare ETFs/index funds. Check StockMirror earnings pages for AI-powered earnings analysis before investing.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always do your own research before making investment decisions.